LPL Financial
PCVX icon

LPL Financial’s Vaxcyte PCVX Stock Holding History

LPL Financial’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Sell
20,075
-7,249
-27% -$394K ﹤0.01% 4296
2026
Q1 		$1.59M Buy
27,324
+6,835
+33% +$371K ﹤0.01% 3719
2025
Q4 		$945K Buy
20,489
+1,172
+6% +$52.4K ﹤0.01% 4127
2025
Q3 		$696K Buy
19,317
+6,582
+52% +$218K ﹤0.01% 4351
2025
Q2 		$414K Buy
12,735
+3,854
+43% +$126K ﹤0.01% 4532
2025
Q1 		$335K Buy
8,881
+2,318
+35% +$185K ﹤0.01% 4497
2024
Q4 		$537K Sell
6,563
-6,902
-51% -$685K ﹤0.01% 4034
2024
Q3 		$1.54M Buy
13,465
+3,947
+41% +$356K ﹤0.01% 2977
2024
Q2 		$719K Buy
9,518
+956
+11% +$65.1K ﹤0.01% 3553
2024
Q1 		$585K Sell
8,562
-2,202
-20% -$152K ﹤0.01% 3646
2023
Q4 		$676K Buy
10,764
+1,139
+12% +$59.2K ﹤0.01% 3404
2023
Q3 		$491K Buy
9,625
+1,027
+12% +$50.7K ﹤0.01% 3502
2023
Q2 		$429K Buy
+8,598
New +$408K ﹤0.01% 3565

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LPL Financial's PCVX Position: Q2 2026 in Review

LPL Financial reduced its Vaxcyte (PCVX) stake by 27% in Q2 2026, selling an estimated $394K and leaving 20,075 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #4296.

LPL Financial first reported a position in PCVX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.59M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • LPL Financial held 20,075 shares of Vaxcyte worth $1.17M as of Q2 2026.
  • LPL Financial sold 7,249 Vaxcyte shares in Q2 2026, an estimated $394K.
  • Vaxcyte made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #4296 holding.
  • LPL Financial first reported a position in Vaxcyte in Q2 2023 and has held it in 13 quarters since.
  • LPL Financial's Vaxcyte position peaked at $1.59M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.